Clinical trial · Observational
Moesin Expression in Clear Cell Renal Cell Carcinoma
Expression and Distribution of Membrane-Organizing Extension Spike Protein (Moesin/ MSN) is Associated With Epithelial-Mesenchymal Transition in Clear Cell Renal Cell Carcinoma.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes. Epithelial-mesenchymal transition (EMT) is a phenomenon in which the epithelial cells acquire some mesenchymal criteria as enhanced invasive potential. There are several cell surface molecules that are implicated in EMT. Moesin is one of these molecules that is involved in EMT, which is associated with enhanced invasive potential and poor prognosis. Targeting Moesin by novel therapeutic agents may prevent EMT and improve prognosis of patients with RCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Detection of Moesin in renal cell carcinoma
- timeFrame
- 6 months
- description
- different levels of moesin expression will be correlated with some tumor characteristics as patients' ages, sexes, tumor site, tumor grades, stages and nodal statuses.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. All cases of ccRCC. 2. Tissue blocks with material adequate for immunohistochemical evaluation. 3. All cases with accessible clinical data. Exclusion Criteria: 1. Cases of renal neoplasms other than ccRCC. 2. Patients who received preoperative chemotherapy or radiotherapy. 3. Patients with ccRCC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations. 4. Cases with insufficient/destructed material. 5. Patients with inadequate clinical data.
References
Publications (0)
Data not yet available